New treatments for heart disease
Heart failure is one of the main causes of disability and mortality from cardiovascular pathology, its incidence is steadily increasing. It develops as a result of decompensation of other diseases of the cardiovascular system, such as hypertension, arrhythmia, cardiomyopathy, inflammatory heart diseases, etc. In this case, there is fluid retention in the body, volume overload and the formation of edematous syndrome. It is the progressive increase in fluid stagnation in the body that leads to death. Therefore, dehydration therapy is an important component of the treatment of patients with heart disease.
According to world clinical guidelines, diuretics are indicated for patients with acute and chronic heart failure II-IV FC, patients with hypertension in order to reduce clinical symptoms and signs of the disease, reduce the risk of hospitalization. With a low left ventricular ejection fraction and signs of congestion, diuretics are prescribed in combination with ACE inhibitors, beta-blockers, aldosterone antagonists. A rational choice of a diuretic should take into account its effectiveness, tolerability, affordability, convenience for use, taking into account the age and clinical manifestations of the patient
Lasix and heart disease
In the active phase of congestion, diuresis should exceed the amount of fluid drunk by 1-2 l / day, with a decrease in body weight of about 1 kg / day. Loop diuretics, such as Lasix, have the most pronounced diuretic effect and ways to achieve this goal. Lasix begins to act already in the first hour after administration, the duration of action is up to 8 hours. It inhibits Na+/2Cl-/K+ transport in the ascending loop of Henle in the kidneys, which enhances sodium excretion and, as a result, increases diuresis. Lasix has a natriuretic effect, which reduces vascular reactivity to catecholamines, which is increased in patients with arterial hypertension. Loop diuretics also act on the renin-angiotensin-aldosterone system (RAAS). Like RAAS inhibitors, diuretics slow down the remodeling and development of left ventricular dysfunction, and slow down myocardial fibrosis. Clinical studies on furosemide show improvements in left ventricular function, exercise tolerance, functional class, mortality, and length of hospital stay in patients with heart failure.
Lasix is more affordable than other loop diuretics, which increases patient compliance. This undoubtedly reduces the risk of cardiovascular events, including fatal ones. Given the high efficiency, speed of action, economic availability of Lasix, it should be given preference in the choice of therapy for acute and chronic heart failure, hypertension.